NCT07071558View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

February 26, 2026

Study Completion Date

February 26, 2026

Conditions
Respiratory Syncytial Virus Immunization
Interventions
BIOLOGICAL

RSV vaccine formulation 1 dose

Suspension for injection. Route of administration: IM injection

BIOLOGICAL

RSV vaccine formulation 2 dose

Suspension for injection. Route of administration: IM injection

BIOLOGICAL

RSV vaccine formulation 3 dose

Suspension for injection. Route of administration: IM injection

BIOLOGICAL

RSV vaccine formulation 4 dose

Suspension for injection. Route of administration: IM injection

BIOLOGICAL

RSV vaccine formulation 5 dose

Suspension for injection. Route of administration: IM injection

BIOLOGICAL

RSV vaccine formulation 6 dose

Suspension for injection. Route of administration: IM injection

BIOLOGICAL

RSV vaccine formulation 7 dose

Suspension for injection. Route of administration: IM injection

BIOLOGICAL

RSV vaccine formulation 8 dose

Suspension for injection. Route of administration: IM injection

Trial Locations (6)

2500

Site # 0361003, Wollongong

3124

Site # 0361001, Camberwell

3153

Site # 0361002, Bayswater

4006

Site # 0361006, Brisbane

4215

Site # 0361004, Southport

4506

Site # 0361005, Morayfield

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY